As nearly all studies investigating CD52 expression by aggressive B-cell neoplasms were performed prior to the establishment of our current working definitions of DHL and DEL, such studies failed to differentiate these more aggressive lymphomas from conventional DLBCL. The gene discussed is CD52; the disease is B-cell neoplasm.